echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Blood: Darafinil plus trametinib for relapsed/refractory BRAF V600E mutant hair cell leukemia

    Blood: Darafinil plus trametinib for relapsed/refractory BRAF V600E mutant hair cell leukemia

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hairy cell leukemia (HCL) is a rare inert B-cell proliferative malignant hematopathy that is commonly associated


    The study was an open-label, Phase 2 clinical trial that enrolled patients with positive HCL of BRAF V600E mutations who did not respond to first-line therapy with purine analogues or who relapsed after previous treatment with



    Patients with


    The most common treatment-related adverse effects were fever (58.


    In summary, dalafinil plus trametinib demonstrated a durable response and controlled safety in patients with HCL positive for relapsed/refractory BRAF V600E mutations, consistent with what had previously been observed in patients with other indications, and could be considered as a treatment option


    Original Source:

    Kreitman Robert J,Moreau Philippe,Ravandi Farhad et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.